<![CDATA[ADC Receives Orphan Drug Designation in Small Cell Lung Cancer]]>
A B7-H3–targeted antibody-drug conjugate (ADC) risvutatug rezetecan (GSK’227; formerly HS-20093) was granted orphan drug designation by the FDA on December 10 for the treatment of patients with small cell lung cancer.1 The designation was supported by …